Many studies have shown that IL-1β blockers, such as anti-IL-1β monoclonal antibody, specifically block the inflammatory signaling cascade, which provides an effective treatment for obesity-related inflammation, insulin resistance, type II diabetes, and autoimmune diseases, like type I diabetes [24, 25]. This evidence concerns the gene IL1B and obesity disorder.